SecBot SecBot
SECBOTREPLAY Home › Report › EW

EW · Edwards Lifesciences reported Q3 2026 adjusted EPS of $0.80, beating…

Edwards Lifesciences Corp · 8-K filed Nov 4, 2026 at 16:21 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 4, 2026 at 16:21 ET

Edwards Lifesciences reported Q3 2026 adjusted EPS of $0.80, beating the $0.74 consensus by 8.1%, on revenue of $1.72B, above the $1.68B consensus. The company raised full-year 2026 sales growth guidance to approximately 11.5% (from 10-11%), TAVR growth to 9.0-9.5%, and adjusted EPS guidance to $2.97-$3.05. TMTT sales grew 44% YoY to $207M, and the PROGRESS trial data and final TAVR NCD were highlighted as key catalysts.

  • Q3 2026 sales grew 10.5% to $1.72B, constant currency growth 11.2%
  • Q3 adjusted EPS $0.80, up 19% YoY, beating consensus of $0.74
  • TAVR sales grew 8.0% to $1.24B, constant currency growth 8.8%
  • TMTT sales grew 44.0% to $207M, constant currency growth 45.6%

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access